Mitsubishi Electric


UCB life scientists use robots to test cells by the billion

04/10/2018 11:36:05
Download Press Release
ImagesClick Image for 300dpi jpg fileUCB life scientists use robots to test cells by the billion

An automated primary antibody screening workcell for early stage development of potential new treatments for central nervous system and immunology disorders has been designed and constructed for UCB S.A. by Peak Analysis and Automation (PAA) Ltd. Built around a Mitsubishi Electric robot, the workcell speeds up the process of antibody discovery by allowing the screening of billions of antibody producing B cells.

UCB S.A. is a multinational biopharmaceutical company headquartered in Brussels, Belgium, that focuses primarily on the research and development of neurological and immune system related medications. The company selected PAA Ltd. for the development of an automated solution for vital cell screening processes that would not have been practical to achieve manually. PAA designs automated workcells for the pharmaceutical, biotechnology, healthcare and genomic research industries.

To become a therapeutic candidate an antibody is required to have many desirable properties. As more is understood about the biochemical and biophysical properties of antibodies, so the list of desirable properties becomes longer. This quest for desirable properties produces more challenges for the area of antibody discovery; more antibodies need to be screened, tested and assessed, to allow the selection of the most suitable antibodies to progress. The process is underpinned by the careful design and selection of appropriate primary and secondary screening assay.

The sheer number of antibody subjects involved makes the process an ideal candidate for automation: the workcell operates by combining high-throughput cell culture screening and identification with the isolation of single antigen specific B cells using a proprietary technique known as the ‘fluorescent foci' method.

The robot facilitates extremely efficient interrogation of the natural antibody repertoire. In a typical early stage screening campaign, a billion antibody producing B cells can be screened to find the ones with some of the desirable properties, a number that would be all but unimaginable if manual techniques were used. “The workcell’s efficient sampling allows the fast discovery of those few antibodies which have required characteristics.” explains Dr Malcolm Crook, a Technical Director at PAA.

With the workcell, the robot is used to seed the cells into barcoded 96-well tissue culture plates at a density between 500 and 5000 cells per well. A typical experiment may use up to 500 plates. The robot then moves the filled plates to an incubator station where the cells divide and produce antibody.

After a week’s incubation the plates are moved by the robot onto a conveyor so that they can be transferred onto a screening workcell. In the screening workcell the cell culture supernatant is sampled and transferred to an assay plate by the robot. A carefully designed homogeneous, plate based, fluorescent screening assay is used to identify wells containing an antibody specific to the target protein.

The plates are then transferred into the picking workcell where the positive-well cell culture supernatants are cherry picked by the robot and consolidated onto a barcoded master plate. Freezing media is added to the picked wells and the plate containing the cells is frozen down to -80°C. Further highly detailed analyses follow, at which stage it is possible to collect the genes of the best individual antibodies and go on to discover and develop therapies for specific diseases.

A key benefit of the antibody discovery workcell for companies like UCB is that it reduces the time required to identify potential candidate antibodies compared to manual methods. Delivering useful starting points from which to allow subsequent discovery of therapies and treatments in the downstream antibody discovery process far more quickly than was previously possible. It also allows multiple projects to be carried out in parallel, thus addressing a broad spectrum of disease mediators.

The workcell is based on a Mitsubishi Electric robot with six axes of movement. In this application it has also been mounted on a ballscrew-driven travel base so that it can move between two locations within the workcell to perform different tasks. This linear movement is fully integrated with the robot’s own motion axes, using a Mitsubishi Electric SSCNet high speed motion control network. PAA fitted the robot with a standalone controller with SSCNet onboard, although Mitsubishi Electric also uniquely offers robots that can be controlled via an integrated PLC rack-mounted robot controller.

The robot is a Mitsubishi Electric model RV7-FLM-D1-S15, a unit that is popular for a range of applications from life sciences and precision assembly to manufacturing and materials handling. It weighs in at less than 67kg, but can lift 7kg, has a reach of over 900mm and a positioning accuracy of 0.02mm. Its waist axis can rotate through ±240deg, which gives it an all-around working envelope. Significantly this robot model is rated to IP67, so can be used in demanding environments. It also offers very fast cycle times and has many safety features such as settable limits for speed, position and torque.

Crook sums up: “Only by starting with a very large number of cells is it possible to identify those few antibodies in early stage screening from which new treatments can be subsequently developed and only robotic automation makes this a viable process.”

Learn more about the background to this project by watching UCB’s core antibody discovery process video here:

See how Mitsubishi Electric can respond to today’s automation demands:

Image Caption: An automated antibody screening workcell has been designed and built by Peak Analysis and Automation (PAA) Ltd for multinational biopharmaceutical company UCB. Mitsubishi Electric robots are used to speed-up the process of antibody discovery by allowing the screening of billions of antibody producing B cells.
[Source: UCB, Peak Analysis and Automation (PAA) Ltd.]

The image(s) distributed with this press release are for editorial use only and are subject to copyright. The image(s) may only be used to accompany the press release mentioned here, no other use is permitted.

All third party trademarks and/or registered trademarks are the property of their respective owners and are acknowledged.

Note to Editor: if you would like the text in another language please contact Philip Howe at DMA Europa –

About Mitsubishi Electric

With nearly 100 years of experience in providing reliable, high-quality products, Mitsubishi Electric Corporation (TOKYO: 6503) is a recognised world leader in the manufacture, marketing and sales of electrical and electronic equipment used in information processing and communications, space development and satellite communications, consumer electronics, industrial technology, as well as in products for the energy sector, transportation and building equipment.

With around 145,817 employees the company recorded consolidated group sales of approximately 40.7 billion dollars* in the fiscal year that ended on March 31, 2019.

Our sales offices, research & development centres and manufacturing plants are located in over 30 countries.

Factory Automation EMEA

Mitsubishi Electric Europe B.V., Factory Automation EMEA has its European headquarters in Ratingen near Dusseldorf, Germany. It is a part of Mitsubishi Electric Europe B.V., a wholly owned subsidiary of Mitsubishi Electric Corporation, Japan.

The role of Factory Automation EMEA is to manage sales, service and support across its network of local branches and distributors throughout the EMEA region.
*Exchange rate 111 Yen = 1 US Dollars, last updated 31.03.2019 (Source: Tokyo Foreign Exchange Market)

Editor Contact

DMA Europa Ltd : Philip Howe
Tel: +44 (0)1562 751436 Fax: +44 (0)1562 748315

Company Contact

Mitsubishi Electric Europe B.V. : Monika Torkel
Tel: +49 (0)2102 486-2150 Fax: +49 (0)2102 486 7780

  [ Back ]  
About the DMA Group Click to Read More